Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873782 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNACETP | |
| SCHEMBL23416780 | 0.84 | — | — | |
| SCHEMBL20033681 | 0.84 | — | — | |
| SCHEMBL4922 | 0.72 | — | — | |
| SCHEMBL473898 | 0.72 | — | — | |
| SCHEMBL11569 | 0.72 | — | — | |
| SCHEMBL5841 | 0.72 | — | — | |
| SCHEMBL30782439 | 0.72 | — | — | |
| SCHEMBL3117621 | 0.71 | — | — | |
| SCHEMBL23336021 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904502-B1 | ANTIARRHYTHMIC PRECURSOR COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | ARYX THERAPEUTICS INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7498449-B2 | Antiarrhythmic precursor compounds, methods of synthesis and methods of use | ARYX THERAPEUTICS (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | ARYX THERAPEUTICS (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060640-A1 | Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use | SCN11A, SCN10A, CYP4F11 | ALDH1A1 800/4885LMNA 721/4885CETP 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.